Publish in this journal
Journal Information
Vol. 54. Num. 5.May 2018
Pages 241-300
Vol. 54. Num. 5.May 2018
Pages 241-300
Letter to the Editor
DOI: 10.1016/j.arbr.2018.03.001
Full text access
Comments on the SEPAR Guidelines for the Diagnosis and Treatment of Drug-Resistant Tuberculosis
Comentarios a la normativa SEPAR de diagnóstico y tratamiento de la tuberculosis con resistencia a fármacos
Visits
147
José A. Camineroa,b,c,
Corresponding author
jcamlun@gobiernodecanarias.org

Corresponding author.
, Joan A. Caylác,d, José-María García-Garcíac,e, Francisco J. García-Pérezc,f, Juan J. Palaciosc,g, Juan Ruiz-Manzanoc,h,i
a Servicio de Neumología, Hospital General de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Las Palmas, Spain
b Unidad de Tuberculosis con Multi-Drogo Resistencia, Unión Internacional contra la Tuberculosis y Enfermedades Respiratorias (La Unión), París, France
c Programa Integrado de Investigación en Tuberculosis (PII TB) de la Sociedad Española de Neumología y Cirugía Torácica SEPAR, Barcelona, Spain
d Servicio de Epidemiologia, Agència de Salut Pública de Barcelona, CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
e Unidad de Gestión Clínica de Neumología, Hospital Universitario San Agustín, Avilés, Asturias, Spain
f Servicio de Neumología, Hospital Universitario de La Princesa, Madrid, Spain
g Unidad de Referencia Regional de Micobacterias, Servicio de Microbiología, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
h Servicio de Neumología, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
i CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain
This item has received
147
Visits
Article information
Full Text
Bibliography
Download PDF
Statistics
To the Editor,
Full Text

We are grateful to Dr. Pascual for his insightful comments1 on our recently published guidelines on the diagnosis and treatment of drug-resistant tuberculosis (TB).2 His letter addresses 2 points that we would like to discuss further.

We fully agree with the first of his comments, regarding the good anti-Mycobacterium tuberculosis activity of bedaquiline and delamanid. As shown in Table 3 of our guidelines,2 the effectiveness of these new drugs prompted us to include them among the core drugs (our group 4) instead of among the add-on agents (Group D) recommended in the 2016 WHO recommendations3; we agree that these 2 drugs should have been included in WHO group C.3 As early as 2015, our group published an article in the European Respiratory Journal, proposing that these new drugs (along with linezolid) should even be positioned above second-line injectable drugs.4 The reason for not including these drugs in treatment regimens from the outset is not so much financial, but because we feel that evidence for such use is still scant. The inclusion of these drugs in group 4 illustrates our view: they are very good but evidence is still lacking. However, by including them in group 4, we are providing the option for their use in MDR-TB regimens.

As for shorter MDR-TB regimens, Dr. Pascual rightly points out that many issues remained unclear in the 2016 WHO publication.3 For this reason, and because of concerns surrounding the applicability of these regimens in practice, the WHO subsequently published an article which addressed many of these controversies.5 In it, they stated that the decision to use shorter regimens should not be based on sensitivity testing to the drugs in the regimen, other than fluoroquinolones or second-line injectables. This is because sensitivity results for these drugs, including pyrazinamide, are unreliable. The authors go so far as to say that even if resistance to pyrazinamide is observed, the clinician can consider using these shorter regimens.5 Furthermore, our recommendation not to use these regimens in pregnant women and in extrapulmonary TB is based on a lack of evidence, even though we are aware that they are used in these patient groups in some countries.

References
[1]
J.F. Pascual Pareja
Comentarios al tratamiento de la tuberculosis con resistencia
Arch Bronconeumol, 54 (2018), pp. 297
[2]
J.A. Caminero, J.A. Caylà, J.M. García-García, F.J. García-Pérez, J.J. Palacios, J. Ruiz Manzano
Diagnóstico y tratamiento de la tuberculosis con resistencia a fármacos
Arch Bronconeumol, 53 (2017), pp. 501-509 http://dx.doi.org/10.1016/j.arbres.2017.02.006
[3]
World Health Organization
WHO treatment guidelines for drug-resistant tuberculosis. 2016 update
World Health Organization Document, (2016)pp. 1-59
WHO/HTM/TB/2016.04
[4]
J.A. Caminero, A. Scardigli
Classification of antituberculosis drugs: a new proposal based on the most recent evidence
Eur Respir J, 46 (2015), pp. 887-893 http://dx.doi.org/10.1183/13993003.00432-2015
[5]
World Health Organization
Frequently asked questions about the implementation of the new WHO recommendation on the use of the shorter MDR-TB regimen under programmatic conditions. Version: 20
(2016, December)

Please cite this article as: Caminero JA, Caylá JA, García-García JM, García-Pérez FJ, Palacios JJ, Ruiz-Manzano J. Comentarios a la normativa SEPAR de diagnóstico y tratamiento de la tuberculosis con resistencia a fármacos. Arch Bronconeumol. 2018;54:298.

Copyright © 2018. SEPAR
Idiomas
Archivos de Bronconeumología (English Edition)

Subscribe to our Newsletter

Article options
Tools
es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?